Credit: Getty Images. Use of analog vs human insulin in patients receiving hemodialysis is associated with a lower risk for major adverse cardiovascular events, hospitalization, and death. Treatment ...

A trial led by University of Pittsburgh researchers and published today in The Lancet Diabetes & Endocrinology adds nuance to ...

A 400-participant trial found long-acting insulin glargine reduced dangerous low blood sugar and nighttime hypoglycemia in ...

In The Lancet Diabetes & Endocrinology, Jing Luo and colleagues present the HumAn-1 trial, an important contribution to the literature on type 1 diabetes in low-income and middle-income countries ...

These second-generation basal insulin analogs, Gla-300 and IDeg-100, also had similar safety profiles, investigators found. A new study of second-generation basal insulin analogs shows insulin ...

The U.S. Food and Drug Administration (FDA) has approved Merilog, a biosimilar to the widely used insulin product Novolog (insulin aspart), to enhance glycemic control in adults and children with ...

GZR4 demonstrated statistically significant HbA1c reductions compared with insulin glargine U100 and insulin degludec, with no reported severe hypoglycemic events. Topline results were announced from ...

Please provide your email address to receive an email when new articles are posted on . Technsophere insulin conferred a similar HbA1c as a rapid-acting analog for children and adolescents with ...

Two long-acting insulin analogs have been developed for use as "basal" components of insulin treatment regimens: glargine and detemir. (Insulin glargine has US Food and Drug Administration [FDA] ...

The U.S. Food and Drug Administration has approved Sanofi-Aventis's Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric patients with diabetes mellitus.